Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Curr Opin Cardiol. 2013 May;28(3):344-53. doi: 10.1097/HCO.0b013e328360443f.
Drug-refractory ventricular tachycardia in the setting of structural heart disease results in frequent implantable cardioverter defibrillator therapies and an increased risk of heart failure. Management requires catheter ablation procedures for effective suppression of the arrhythmia.
Imaging and electroanatomic mapping technologies provide new insights into the myocardial structural abnormalities responsible for ventricular tachycardia. Integration of imaging data with three-dimensional mapping systems coupled with improved targeting of abnormal electrical signals may improve the ablation outcomes. New ablation tools show promise for the effective ablation of previously unreachable myocardial ventricular tachycardia circuits.
Catheter ablation procedures have evolved over the last 2 decades. Improved technology may contribute to more widespread utilization of catheter ablation in the future.
结构性心脏病患者出现药物难治性室性心动过速，会导致频繁的植入式心脏复律除颤器治疗，心力衰竭风险增加。管理需要导管消融术来有效抑制心律失常。
影像学和电生理标测技术为导致室性心动过速的心肌结构异常提供了新的见解。将影像学数据与三维标测系统相结合，并结合异常电信号的靶向治疗，可能会改善消融效果。新的消融工具为有效消融以前无法到达的心肌室性心动过速回路提供了希望。
导管消融术在过去 20 年中不断发展。改进的技术可能会促进未来更广泛地应用于导管消融术。
